In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...

Things often seem either black or white within the targeted protein degradation (TPD) space. The biology behind degrading therapeutic targets that are difficult or dangerous to inhibit is well ...

Lycia Therapeutics Inc. has reported progress in its immunology pipeline that comprises lysosomal targeting chimera (LYTAC)-based protein degradation therapies. The company is advancing its two lead ...